Implementing the Right Therapy at the Right Time
Leading a new path in healthcare innovation, MET-TEST offers a higher level of diagnostic insight to improve management of cardiac and pulmonary diseases. With increasing pressure on the healthcare system to improve outcomes and contain costs, MET-TEST builds upon well established physiological principles to enable healthcare providers and organizations to achieve a new level of patient management.
Cardiovascular disease (CVD) runs a full spectrum from normal cardiovascular function to mild, moderate and severe heart disease with or without symptoms in at-risk individuals. The MET-TEST chronic disease management program helps clinicians improve clinical care of patients in two ways:
Precise Cardiovascular (CV) Risk Stratification: Atherosclerosis is a chronic inflammatory process that cause endothelial dysfunction followed by microvascular damage and is sometimes followed by the development of obstructive coronary artery disease resulting in left ventricular (LV) remodeling over time. This slow remodeling process causes cardiac dysfunction during exercise and reduces peak cardiac function (peak VO2) with disease progression. Poor functional capacity (low peak VO2) and inducible ischemia during exercise are well recognized as two main determinants of CV events and mortality. Our CPET program accurately provides individualized risk-stratification regardless of symptoms based on these two parameters which are in turn used to guide intensity of lifestyle, medical and surgical interventions. Serial testing provides an accurate measure of disease progression or regression, thus enabling patients to enhance and monitor their CV health over time. No other type of data provides clinicians and patients with this degree of precision and insight to improve long-term outcomes and reduce long-term healthcare costs.
Unexplained Exercise Intolerance: Patients often present with shortness of breath, chest pain and fatigue where routine cardiac and pulmonary testing does not reveal a clear etiology. MET-TEST is able to diagnose three invisible disease states that are quite common in society but not readily detected by resting and imaging studies. These disease states include physiologically significant micro-vascular ischemia, diastolic dysfunction and pulmonary circulation abnormalities during exertion. MET-TEST works with providers to properly evaluate and treat such patients and prove response to therapy with improvement in symptoms and increase in exercise capacity on a case by case basis.
MET-TEST brings over a decade of cardiac and pulmonary disease management experience to our customers. The Introduction Video provides a 20 minute overview of our business model. The first 10 minutes cover logistics and operations and the last 10 minutes are clinical in nature.
We look forward to working with you to take patient management to the next level.